Q2 2024 Summary
Published Jan 22, 2025, 6:07 PM UTC- Montrose is on track to achieve its annual organic growth guidance of 10% to 12%, with strong performance in the first half and confidence in continued growth for Q3 and Q4.
- The company has significantly improved margins, with gross margins increasing due to pricing success and operating leverage, and expects margins to continue improving over time similar to operating EBITDA margins. Additionally, the Matrix acquisition has improved from ~5% to low double-digit EBITDA margins, and is on track to reach mid-teens EBITDA margins by the end of this year, demonstrating successful integration and optimization.
- Montrose expects significant growth in its PFAS-related services, including water treatment, advisory, and testing segments, driven by increasing demand and regulatory requirements, contributing to strong organic growth and secular tailwinds in these businesses over the next several years.
- Lack of transparency on quarterly organic growth figures: Montrose does not disclose quarterly organic growth, instead only providing annual guidance. This lack of detail may concern investors who seek more frequent updates to assess the company's performance and its ability to meet the annual organic growth guidance of 10% to 12%.
- Small impact from recent acquisitions on financial guidance: Despite completing five acquisitions year-to-date and deploying $27 million on Paragon and Spirit, these acquisitions are relatively small with de minimis contributions to the annual guidance. This suggests that the acquisitions are not significantly impacting growth or moving the needle on financial performance, raising concerns about the effectiveness of the company's M&A strategy.
- Potential underestimation of regulatory risks from Supreme Court rulings: Management appears confident that recent Supreme Court decisions, such as the Chevron ruling, will not impact their business or necessitate changes in resource allocation. However, these rulings may introduce regulatory uncertainties and shift influence to state and local regulators, which could affect Montrose's operations and growth if not adequately addressed.
-
Capital Allocation Strategy
Q: Will you surpass your $10M EBITDA acquisition goal? Consider share buybacks?
A: Yes, we have surpassed our goal of acquiring $10 million in EBITDA this year, and the opportunities ahead remain significant. We expect continued acquisition activity in the back half of the year, with a strong outlook for next year. Regarding share buybacks, while the current stock price is attractive, as a high-growth company we prefer to invest in acquisitions with strong returns rather than buy back shares. -
Impact of Chevron Decision
Q: Are you changing M&A or resources due to the Chevron ruling?
A: No, in light of the Supreme Court's Chevron decision, we are not changing our M&A strategy or resource allocation. Regulations impacting us are within the EPA's statutory authority, and we don't anticipate significant business flux due to the ruling. Challenges may arise around technicalities, but our actions remain largely unchanged. -
Gross Margins Improvement
Q: Gross margins are highest ever; what's driving this improvement?
A: Gross margins have improved due to business mix, pricing success, and operating leverage, particularly in our labs. We've built scalable support functions, keeping SG&A within operations flat, leading to increased margins. We expect gross margins to continue improving over time, similar to our EBITDA margins. -
Guidance and Acquisitions
Q: Why reaffirm guidance after spending $27M on acquisitions?
A: The recent acquisitions of Paragon and Spirit were small, contributing a de minimis amount in the back half of this year—not enough to adjust our annual guidance. We had already increased guidance earlier due to strong organic performance and prior acquisitions. These two deals were too small to warrant a further increase, though we may revisit guidance as the year progresses. -
Matrix Margin Improvement
Q: What's left to achieve mid-teens margins at Matrix?
A: When we acquired Matrix, EBITDA margins were around 4.5% to 5%. It's now trending to low double digits and is on track to reach mid-teens by year-end. We've implemented pricing strategies, staffing optimization, and overhead cost reductions. These efforts are largely completed, and the margin improvement will continue into the end of the year. -
Water Treatment and PFAS Growth
Q: When will water treatment business grow year-over-year?
A: Our PFAS water treatment business is up in the second half compared to the first half, and we're expecting growth in the back half of this year, which is included in our guidance. The broader treatment technology business, including water treatment and renewables, is up nicely year-over-year, driven by secular tailwinds expected to benefit us in the medium to long term. -
Organic Growth and Testing Segment
Q: Have you seen increased demand in PFAS testing?
A: Yes, we've seen a step up in demand in our labs due to PFAS testing programs. Our testing segment's growth is all organic, with PFAS being a significant contributor. -
Renewable Services Update
Q: How is the renewable service business progressing?
A: The renewable service business is progressing well. We're expecting nice growth from last year to this year, with further growth in the second half and into 2025. We're back on offense in this business, which is part of our treatment technology portfolio, and see an upward trajectory over the next couple of years.